Altamira Therapeutics Ltd. CYTOF
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.45M | 2.82M | 3.20M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -117.60K | -94.20K | -70.80K | -- | -- |
| Total Operating Expenses | 5.56M | 6.21M | 6.85M | -- | -- |
| Operating Income | -5.56M | -6.21M | -6.85M | -- | -- |
| Income Before Tax | -5.65M | -7.06M | -8.46M | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.65 | -7.06 | -8.46 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.65M | -7.06M | -8.46M | -- | -- |
| EBIT | -5.56M | -6.21M | -6.85M | -- | -- |
| EBITDA | -2.62M | -1.31M | -- | -- | -- |
| EPS Basic | -1.45 | -2.35 | -3.25 | -- | -- |
| Normalized Basic EPS | -0.91 | -1.47 | -2.03 | -- | -- |
| EPS Diluted | -1.45 | -2.35 | -3.25 | -- | -- |
| Normalized Diluted EPS | -0.91 | -1.47 | -2.03 | -- | -- |
| Average Basic Shares Outstanding | 17.24M | 14.29M | 11.33M | -- | -- |
| Average Diluted Shares Outstanding | 17.24M | 14.29M | 11.33M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |